ArticleOrphanet journal of rare diseases2026
Burden of respiratory syncytial virus in spinal muscular atrophy: a retrospective nationwide cross-sectional and birth cohort study.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSpinal muscular atrophy (SMA) is a severe neuromuscular disease associated with a high risk of respiratory complications, yet real-world data on respiratory syncytial virus (RSV) infection in this population remain limited. This study aimed to investigate the severity, hospitalization costs, and seasonal patterns of RSV infections in patients with SMA using real-world data in Taiwan.
methodsThis retrospective study analyzed data from Taiwan's National Health Insurance Research Database from 2009 to 2021. Patients with SMA were identified through at least two outpatient clinic visits and one hospital admission. The analysis included a cross-sectional study and a birth cohort analysis for sensitivity testing. RSV-associated hospitalizations were identified using diagnostic codes for RSV. The main outcomes included ICU admissions, ventilator use, hospitalization costs, timing of RSV onset, and seasonal infection trends.
resultsThis study documented 914 hospitalizations in patients with SMA over 13 years, including 14 RSV infections (1.5%). All RSV-related hospitalizations were documented before age 18. In a birth cohort analysis comparing 110 patients with SMA to 2,103,997 individuals from the general population, patients with SMA demonstrated significantly higher RSV hospitalization rates (9.8% vs. 1.6%), ICU admissions (54.5% vs. 4.7%; p < 0.0001), and ventilator use (54.5% vs. 1.7%; p < 0.0001), with a later mean onset (2.54 ± 2.05 years vs. 1.05 ± 1.05 years; p = 0.0073) and substantially higher hospitalization costs (median 967 [560-6,462] USD vs. 683 [487-1002] USD; p = 0.0480). Infections peaked in fall and winter (72.7%) for patients with SMA. ICU admission rates for RSV increased with age and decreased with later SMA onset.
conclusionsPatients with SMA are at heightened risk for severe RSV infections even beyond infancy, underscoring the need for age-specific and seasonal prevention strategies, particularly for those over two years old.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.